Primus Pharms Drug Patent Portfolio
Primus Pharms owns 3 orange book drugs protected by 12 US patents Given below is the list of Primus Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11918559 | Reduced dose metaxalone formulations | 29 Jul, 2039 | Active |
| US9855334 | Topical compositions comprising a corticosteroid | 11 Mar, 2035 | Active |
| US10064875 | Topical formulations comprising a steroid | 31 Aug, 2030 | Active |
| US10588914 | Topical formulations comprising a steroid | 31 Aug, 2030 | Active |
| US9956231 | Topical formulations comprising a steroid | 31 Aug, 2030 | Active |
| US10179137 | Topical formulations comprising a steroid | 31 Aug, 2030 | Active |
| US9364485 | Topical formulations comprising a steroid | 31 Aug, 2030 | Active |
| US9433630 | Topical formulations comprising a steroid | 31 Aug, 2030 | Active |
| US9439911 | Topical formulations comprising a steroid | 31 Aug, 2030 | Active |
| US9655907 | Topical formulations comprising a steroid | 31 Aug, 2030 | Active |
| US9775851 | Topical formulations comprising a steroid | 31 Aug, 2030 | Active |
| US9877974 | Topical formulations comprising a steroid | 31 Aug, 2030 | Active |
Latest Legal Activities on Primus Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Primus Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 06 Mar, 2024 | US9433630 |
|
Email Notification
Critical
| 05 Mar, 2024 | US11918559 |
| Recordation of Patent eGrant | 05 Mar, 2024 | US11918559 |
| Mail Patent eGrant Notification | 05 Mar, 2024 | US11918559 |
|
Recordation of Patent Grant Mailed
Critical
| 05 Mar, 2024 | US11918559 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 05 Mar, 2024 | US11918559 |
| Patent eGrant Notification | 05 Mar, 2024 | US11918559 |
|
Issue Notification Mailed
Critical
| 14 Feb, 2024 | US11918559 |
|
Email Notification
Critical
| 14 Feb, 2024 | US11918559 |
| Dispatch to FDC | 05 Feb, 2024 | US11918559 |
|
Application Is Considered Ready for Issue
Critical
| 05 Feb, 2024 | US11918559 |
|
Issue Fee Payment Received
Critical
| 23 Jan, 2024 | US11918559 |
|
Issue Fee Payment Verified
Critical
| 23 Jan, 2024 | US11918559 |
| Miscellaneous Incoming Letter | 03 Jan, 2024 | US11918559 |
| PG-Pub Submission | 28 Dec, 2023 | US11918559 |
Primus Pharms's Family Patents
Primus Pharms Drug List
Given below is the complete list of Primus Pharms's drugs and the patents protecting them.
1. Impoyz
Impoyz is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9855334 | Topical compositions comprising a corticosteroid |
11 Mar, 2035
(9 years from now)
| Active |
| US10064875 | Topical formulations comprising a steroid |
31 Aug, 2030
(5 years from now)
| Active |
| US10588914 | Topical formulations comprising a steroid |
31 Aug, 2030
(5 years from now)
| Active |
| US9956231 | Topical formulations comprising a steroid |
31 Aug, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Impoyz's drug page
2. Metaxalone
Metaxalone is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11918559 | Reduced dose metaxalone formulations |
29 Jul, 2039
(14 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Metaxalone's drug page
3. Sernivo
Sernivo is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10179137 | Topical formulations comprising a steroid |
31 Aug, 2030
(5 years from now)
| Active |
| US9364485 | Topical formulations comprising a steroid |
31 Aug, 2030
(5 years from now)
| Active |
| US9433630 | Topical formulations comprising a steroid |
31 Aug, 2030
(5 years from now)
| Active |
| US9439911 | Topical formulations comprising a steroid |
31 Aug, 2030
(5 years from now)
| Active |
| US9655907 | Topical formulations comprising a steroid |
31 Aug, 2030
(5 years from now)
| Active |
| US9775851 | Topical formulations comprising a steroid |
31 Aug, 2030
(5 years from now)
| Active |
| US9877974 | Topical formulations comprising a steroid |
31 Aug, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sernivo's drug page